{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:36:41Z","timestamp":1791121001143,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3471,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>In patients with cirrhosis and type 1 hepatorenal syndrome (HRS), systemic vasodilation, which is mainly attributable to splanchnic vasodilation, plays a critical role in the activation of endogenous vasoconstrictor systems, resulting in renal vasoconstriction and functional renal failure. It has been suggested that the use of splanchnic (and systemic) vasoconstrictors such as terlipressin (a vasopressin analog) or alpha-1-adrenoceptor agonists (midodrine or noradrenaline) may improve renal function in patients with type 1 HRS. Six studies (with only one randomized study in a small series of patients) have shown that terlipressin improves renal function in these patients. However, there is evidence that terlipressin alone may be less effective than terlipressin combined with intravenous albumin in improving renal function. Future randomized studies should confirm this difference and evaluate the impact of terlipressin therapy (with or without intravenous albumin) on survival. Interestingly, in nonrandomized studies, the use of alpha-1 agonists combined with other therapies (octreotide and albumin for midodrine; furosemide and albumin for noradrenaline) has been shown to improve renal function in patients with type 1 HRS. The efficacy and safety of combined therapies including alpha-1 agonists should be confirmed in randomized studies. Finally, preliminary evidence suggests that vasoconstrictor administration may be a novel therapeutic approach targeting vasodilation involved in the mechanism of: (1) renal failure in type 2 HRS; (2) paracentesis-induced circulatory dysfunction; and (3) arterial hypotension induced by byproducts of gram-negative bacteria. Further studies are needed in all these fields. (Hepatology 2006;43:385\u2013394.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21094","type":"journal-article","created":{"date-parts":[[2006,2,22]],"date-time":"2006-02-22T21:49:32Z","timestamp":1140644972000},"page":"385-394","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":110,"title":["The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond"],"prefix":"10.1097","volume":"43","author":[{"given":"Richard","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lebrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20241201","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0168-8278(98)80241-9","article-title":"Pharmacological treatment of portal hypertension: present and future.","volume":"28","author":"Lebrec","year":"1998","journal-title":"J Hepatol"},{"key":"R2-2-20241201","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2005.05.009","article-title":"Evolving consensus in portal hypertension: report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension.","volume":"43","author":"de Franchis","year":"2005","journal-title":"J Hepatol"},{"key":"R3-2-20241201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"R4-2-20241201","first-page":"15","article-title":"Longterm terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"R5-2-20241201","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"R6-2-20241201","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042737-200202000-00009","article-title":"Effect of terlipressin (Glypressine) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.","volume":"14","author":"Halimi","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R7-2-20241201","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.","volume":"36","author":"Ortega","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R8-2-20241201","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebocontrolled clinical trial.","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R9-2-20241201","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.","volume":"29","author":"Angeli","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R10-2-20241201","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.","volume":"40","author":"Wong","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R11-2-20241201","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: a pilot study.","volume":"36","author":"Duvoux","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R12-2-20241201","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","article-title":"Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.","volume":"14","author":"Alessandria","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R13-2-20241201","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.50.1.90","article-title":"Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.","volume":"50","author":"Moreau","year":"2002","journal-title":"Gut"},{"key":"R14-2-20241201","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/jhep.2002.36501","article-title":"Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis.","volume":"36","author":"Moreau","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R15-2-20241201","first-page":"164","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.","volume":"23","author":"Arroyo","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R16-2-20241201","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/jhep.2003.50084","article-title":"Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.","volume":"37","author":"Moreau","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R17-2-20241201","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"R18-2-20241201","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1042\/cs0920433","article-title":"The hepatorenal syndrome.","volume":"92","author":"Moore","year":"1997","journal-title":"Clin Sci"},{"key":"R19-2-20241201","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/jhep.2001.29200","article-title":"New challenge of hepatorenal syndrome: prevention and treatment.","volume":"34","author":"Wong","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R20-2-20241201","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1440-1746.2002.02778.x","article-title":"Hepatorenal syndrome in patients with cirrhosis.","volume":"17","author":"Moreau","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R21-2-20241201","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome.","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"R22-2-20241201","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra035021","article-title":"Management of cirrhosis and ascites.","volume":"350","author":"Gines","year":"2004","journal-title":"N Engl J Med"},{"key":"R23-2-20241201","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.","volume":"41","author":"Alessandria","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R24-2-20241201","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.","volume":"8","author":"Schrier","year":"1988","journal-title":"HEPATOLOGY"},{"key":"R25-2-20241201","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0016-5085(89)91704-6","article-title":"Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.","volume":"97","author":"FernandezSeara","year":"1989","journal-title":"Gastroenterology"},{"key":"R26-2-20241201","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8278(21)80003-3","article-title":"Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis.","volume":"23","author":"Henriksen","year":"1995","journal-title":"J Hepatol"},{"key":"R27-2-20241201","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis.","volume":"42","author":"RuizdelArbol","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R28-2-20241201","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/heart.87.1.9","article-title":"Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.","volume":"87","author":"Moller","year":"2002","journal-title":"Heart"},{"key":"R29-2-20241201","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/0016-5085(91)90734-3","article-title":"Ornipressin in the treatment of functional renal failure in decompensated cirrhosis: effects on renal hemodynamics and atrial natriuretic factor.","volume":"101","author":"Lenz","year":"1991","journal-title":"Gastroenterology"},{"key":"R30-2-20241201","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0168-8278(97)80456-4","article-title":"Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites.","volume":"26","author":"Gadano","year":"1997","journal-title":"J Hepatol"},{"key":"R31-2-20241201","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-0676.2000.020001051.x","article-title":"Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients.","volume":"20","author":"Moller","year":"2000","journal-title":"Liver"},{"key":"R32-2-20241201","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the twoday administration of terlipressin in patients with cirrhosis and hepatorenal syndrome.","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"key":"R33-2-20241201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.","volume":"27","author":"Guevara","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R34-2-20241201","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Longterm therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamin.","volume":"30","author":"Gulberg","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R35-2-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0016-5085(82)90129-9","article-title":"Aminoglycoside nephrotoxicity in cirrhosis: value of urinary 2microglobulin to discriminate functional renal failure from acute tubular damage.","volume":"82","author":"Cabrera","year":"1982","journal-title":"Gastroenterology"},{"key":"R36-2-20241201","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0168-8278(95)80292-4","article-title":"Endogenous factors involved in the control of arterial tone in cirrhosis.","volume":"22","author":"Moreau","year":"1995","journal-title":"J Hepatol"},{"key":"R37-2-20241201","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000539-200107000-00012","article-title":"Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?","volume":"93","author":"Medel","year":"2001","journal-title":"Anesth Analg"},{"key":"R38-2-20241201","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, doubleblind, placebocontrolled, crossover study.","volume":"38","author":"PomierLayrargues","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R39-2-20241201","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1046\/j.1440-1746.2002.02816.x","article-title":"Clinical course, predictive factors and prognosis of hepatorenal syndrome treated with terlipressin: a retrospective analysis.","volume":"17","author":"Colle","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 3","key":"R40-2-20241201","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2036.2004.02115.x","article-title":"Review article: pharmacological treatment of hepatorenal syndrome.","volume":"20","author":"Gines","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R41-2-20241201","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome: a casecontrol study.","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"R42-2-20241201","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jhep.2003.10.024","article-title":"The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation.","volume":"40","author":"Moreau","year":"2004","journal-title":"J Hepatol"},{"key":"R43-2-20241201","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of oral administration of midodrine, an adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.","volume":"28","author":"Angeli","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R44-2-20241201","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.CIR.100.11.1242","article-title":"Pharmacotherapy of neurally mediated syncope.","volume":"100","author":"Benditt","year":"1999","journal-title":"Circulation"},{"key":"R45-2-20241201","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.","volume":"38","author":"Moore","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R46-2-20241201","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0016-5085(96)70068-9","article-title":"Randomized trial comparing albumin, Dextran. 70, and polygeline in cirrhotic patients with ascites treated by paracentesis.","volume":"111","author":"Gines","year":"1996","journal-title":"Gastroenterology"},{"key":"R47-2-20241201","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/gast.1997.v113.pm9247479","article-title":"Paracentesisinduced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis.","volume":"113","author":"RuizDelArbol","year":"1997","journal-title":"Gastroenterology"},{"key":"R50-2-20241201","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/gut.2004.038679","article-title":"Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club.","volume":"54","author":"Wong","year":"2005","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21094","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200603000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:18:43Z","timestamp":1733055523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200603000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21094","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}